To the Editor We congratulate Sanacora et al1 for the publication of their consensus statement in JAMA Psychiatry. The growing amount of literature on this topic has generated interest among patients and physicians, which called for such an important document as the basis for decision-making societies, health care professionals, and regulatory authorities. Until official approval of depression as an indication, off-label uses by medical experts assuming legal, scientific, and medical hazards will increase. On the other hand, ketamine clinics or ketamine wellness centers already offer ketamine as outpatient treatment with unscientific and dangerous methods. To overcome the lack of regulation, consensus statements and their dissemination are of utmost importance.
Kraus C, Lanzenberger R, Kasper S. Ketamine for the Treatment of Depression. JAMA Psychiatry. 2017;74(9):970. doi:10.1001/jamapsychiatry.2017.1770